MedTrace Logo

The Benefits and Risks of Different Menopausal Hormone Replacement Therapy Regimes in the Treatment of Menopause Syndrome

NCT03436303 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-02-19

No results posted yet for this study

Summary

A prospective, open-label, randomized controlled clinical trial to compare the benefits and risks of half-dose or standard-dose conjugated equine estrogens(CEE) plus natural progesterone or dydrogesterone in menopausal hormone therapy .

Conditions

  • Menopause Syndrome

Interventions

DRUG

CEE 0.625 mg/MP 100mg

CEE 0.625 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years

DRUG

CEE 0.3 mg/MP 100mg

CEE 0.3 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years

DRUG

CEE 0.625mg/dydrogesterone

CEE 0.3 mg/dydrogesterone 10mg daily for the last 12 days of every 28 days for two years

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Aijun Sun, MD · Peking Union Medical College Hospital,Peking Union Medical College, Chinese Academy of Medicine Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-01
Primary Completion
2018-06-01
Completion
2018-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03436303 on ClinicalTrials.gov